tirzepatide surmount-1 percent weight loss 72 weeks Trial 🔴Tirzepatide for obesity and diabetes
Description
When tirzepatide slows gastric emptying, adequate hydration becomes even more important
Large randomized trials, including the SURPASS program, have demonstrated substantial reductions in glycated hemoglobin (HbA1c) and body weight compared with established therapies [1-4]
Tirzepatide (known as Mounjaro) is a dual-action GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist
Not everyone experiences the same timeline
